Spots Global Cancer Trial Database for Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
Official Title: Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
Study ID: NCT03260192
Conditions
Interventions
Study Description
Brief Summary: Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
Detailed Description: Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Sunyat-sen Memorial Hospital, Guandong, Guangdong, China
Contact Details
Name: qiang Liu
Affiliation: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
